Dupuytren's Contracture News and Research

RSS
Dupuytren's contracture is a condition that impacts the fingers and the hands, causing at least one finger, and possibly several, to bend toward the palm of the hand. Also known as Dupuytren's disease, the condition can affect both hands, including the thumbs.
BioSpecifics 2010 net loss decreases to $1.5 million

BioSpecifics 2010 net loss decreases to $1.5 million

Loyola offers new, nonsurgical treatment for Dupuytren's contracture

Loyola offers new, nonsurgical treatment for Dupuytren's contracture

Journal of Hand Surgery publishes XIAFLEX CORD II phase III clinical trial

Journal of Hand Surgery publishes XIAFLEX CORD II phase III clinical trial

BioSpecifics Technologies third quarter net loss increases to $0.5 million

BioSpecifics Technologies third quarter net loss increases to $0.5 million

BioSpecifics Technologies second-quarter total revenues decrease to $0.9 million

BioSpecifics Technologies second-quarter total revenues decrease to $0.9 million

BioSpecifics' partner Auxilium provides update on XIAFLEX

BioSpecifics' partner Auxilium provides update on XIAFLEX

BioSpecifics Technologies total revenues for first-quarter increase to $2.7M

BioSpecifics Technologies total revenues for first-quarter increase to $2.7M

BioSpecifics Technologies' XIAFLEX now available to Dupuytren's contracture patients in the U.S.

BioSpecifics Technologies' XIAFLEX now available to Dupuytren's contracture patients in the U.S.

FDA approves Xiaflex drug for treatment of Dupuytren's contracture

FDA approves Xiaflex drug for treatment of Dupuytren's contracture

BioSpecifics Technologies' XIAFLEX receives FDA approval

BioSpecifics Technologies' XIAFLEX receives FDA approval

Xiaflex receives FDA approval for treatment of Dupuytren's contracture

Xiaflex receives FDA approval for treatment of Dupuytren's contracture

Pfizer and Auxilium Pharmaceuticals announce completion of European MAA validation phase for XIAFLEX

Pfizer and Auxilium Pharmaceuticals announce completion of European MAA validation phase for XIAFLEX

BioSpecifics Technologies revenues increases by 100% for the third quarter ended September 30, 2009

BioSpecifics Technologies revenues increases by 100% for the third quarter ended September 30, 2009

Auxilium Pharmaceuticals reports increased net revenues of $42.1 million in third quarter 2009

Auxilium Pharmaceuticals reports increased net revenues of $42.1 million in third quarter 2009

FDA Advisory Committee recommends marketing approval for Auxilium's XIAFLEX to treat Dupuytren's contracture

FDA Advisory Committee recommends marketing approval for Auxilium's XIAFLEX to treat Dupuytren's contracture

Phase III clinical trial results of XIAFLEX published in a journal

Phase III clinical trial results of XIAFLEX published in a journal

CORD I phase III clinical trial results of XIAFLEX published

CORD I phase III clinical trial results of XIAFLEX published

New method for treating hand disorder discovered

New method for treating hand disorder discovered

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.